Cycloreg

Quick links to important sections

Cycloreg

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cycloreg

Property Description
Active ingredient Norethisterone (Norethindrone)
Form Oral Tablet
Pharmacological class Progestogen (Progestin)
General purpose Regulation of menstrual cycles and hormonal balance
Origin Synthetic Steroidal Hormone (Second-generation progestin)

What Type of Medicine is Cycloreg? (Identity and Classification)

Cycloreg is an oral tablet preparation whose established active component is Norethisterone (Norethindrone). This medicine belongs to the pharmacological class of Progestogens (or Progestins), which are synthetic compounds designed to mimic the actions of the natural hormone progesterone. The drug is classified as a single-ingredient synthetic steroidal hormone intended for systemic effect. It is typically a prescription-only medication, indicating its use requires professional oversight.

As a Progestogen, Norethisterone acts as a specific chemical messenger that binds to and activates the body's progesterone receptors. This progestin classification is essential to its role in regulating the menstrual cycle and managing hormonal imbalance. The ability of Cycloreg to introduce this consistent progestational activity into the body is its core therapeutic function, widely recognized for establishing stability in the reproductive system.


Is Norethisterone a Natural or Synthetic Hormone? (Composition and Origin)

Norethisterone is a strictly synthetic hormone, specifically classified as a second-generation progestin. This designation indicates it is a man-made version chemically adapted from the testosterone structure to achieve high effectiveness when administered via the oral route. This synthetic modification makes the substance stable and potent for absorption, distinguishing it from the natural progesterone molecule.

The preparation Cycloreg is typically manufactured and marketed as a specific brand presentation of the Norethisterone ingredient. It is designed as a single-ingredient product, containing only Norethisterone combined with standard, inactive solid pharmaceutical excipients required to form the oral tablet. This focused, single-ingredient formulation is beneficial when a practitioner aims to address an underlying hormonal imbalance with dedicated progestin therapy alone, without requiring simultaneous estrogen administration.


What is the General Purpose of Cycloreg's Action? (High-Level Function)

The general therapeutic purpose of Cycloreg is to help regulate and control the menstrual cycle and establish a consistent hormonal state within the body. By mimicking natural progesterone after being absorbed, the medicine works by stabilizing the growth and timely shedding of the endometrium (the lining of the uterus). This high-level action is foundational to managing general symptoms arising from hormonal imbalance and the resulting menstrual irregularities. For instance, this mechanism is clinically employed to establish a predictable cycle where one might be absent due to a lack of hormonal stimuli.

Regulatory References

  1. Norethindrone Acetate Tablets, USP - DailyMed
  2. Norethindrone Acetate Tablets - DailyMed (NIH)

What side effects are possible with Cycloreg?

Possible Side Effects and Safety Information

The safety profile of Cycloreg, which contains Norethisterone, is defined by regulatory documents that classify potential adverse reactions based on frequency and affected body system. These classifications outline the official risk spectrum, from common effects to rare, serious adverse events.


Official Adverse Reaction Classification

Adverse reactions are formally grouped by regulatory authorities. The most frequently documented effects, often classified as Very Common, include headache, breast tenderness or pain, and menstrual irregularities (such as spotting or amenorrhea).

Common reactions typically involve the nervous system and gastrointestinal system, often listing nausea, dizziness, changes in body weight, depression, and acne.

These effects are categorized under System-Organ-Classes such as Reproductive System and Breast Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.


Serious Safety Constraints and Risks

Regulatory labeling specifies a potential for serious, though typically Rare, adverse reactions. The most significant are thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism), severe hepatic dysfunction, and anaphylactic/serious hypersensitivity reactions.

Safety is strictly constrained by contraindications, which prohibit the use of Cycloreg in certain patients. These include individuals with known or suspected pregnancy, current or history of thromboembolic disease, severe hepatic impairment (liver disease), and hormone-sensitive malignancies (e.g., certain breast cancers). Menstrual irregularities are officially documented as occurring more frequently during the initial months of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Cycloreg (Norethisterone) overdose is documented with specific, non-life-threatening manifestations and clear mandatory actions for patients and caregivers.

Domain Official Regulatory Statement
Documented Manifestations: Overdosage may manifest with nausea, vomiting, breast enlargement, and later, vaginal bleeding.
Severity Classification: Overdose is generally not expected to be dangerous, according to regulatory sources, but strictly requires medical supervision.
Emergency Action: Seek immediate medical attention and/or contact a Poison Help line upon suspected overdosage.

Resulting Overdose Structure

Official regulatory statements confirm the protocol for Norethisterone overdose management:

  • No specific antidote is known for the overdose, which defines the treatment approach.
  • Treatment must be symptomatic and supportive to manage the manifestations.
  • Gastric lavage may be employed as a procedural step if a large dose was ingested and the patient is seen within four hours of ingestion.

The regulatory documents define the overdose profile by its specific, limited cluster of manifestations and the confirmed absence of a known antidote. The mandatory course of action is to seek immediate medical attention and initiate necessary symptomatic and supportive treatment under medical guidance. This structure ensures all suspected overdose cases are triaged to the healthcare system for necessary observation and management based strictly on the official label.

Therapeutic Uses of Cycloreg

Cycloreg is a prescription medication indicated for the supportive management of symptoms associated with certain circulatory and inflammatory conditions. Its primary role is to assist patients by mitigating the severity of chronic localized discomfort and supporting overall tissue health in affected areas. This medicine is generally incorporated into a broader treatment plan when the goal is to stabilize symptom manifestation over time and support the patient's capacity for daily function.

The clinical scenarios for using Cycloreg involve addressing issues such as persistent vascular discomfort and chronic localized swelling. It is utilized for the long-term care of specific peripheral circulatory issues and as a means of **temporary relief from associated functional limitations.


Quick Fact: Relief for Chronic Vascular Discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Cycloreg?

Eligibility for Cycloreg (Norethisterone) is strictly governed by regulatory classifications, primarily focused on absolute contraindications and specific high-risk conditions, as defined in official prescribing information.


Contraindicated Populations (Must Not Use)

Individuals who possess any of the following conditions or statuses are strictly prohibited from using Cycloreg, as stated in regulatory labels:

  • Known or Suspected Pregnancy
  • Active or Recent Thromboembolic Disorders (e.g., Deep Vein Thrombosis, Pulmonary Embolism, Stroke)
  • Active Liver Disease or Severe Liver Impairment (including liver tumors)
  • Known, Suspected, or History of Hormone-Sensitive Cancers (e.g., Breast Cancer)
  • Undiagnosed Abnormal Genital Bleeding

Populations Requiring Restricted or Conditional Use

Use is allowed only with careful medical oversight for individuals with specific comorbidities due to the risk of exacerbation, primarily linked to potential fluid retention:

  • Renal Dysfunction or Cardiac Conditions
  • Epilepsy or Migraine Headaches
  • Uncontrolled Hypertension or Diabetes Mellitus

Age and Physiological Status

Cycloreg is primarily indicated for Adult Women of reproductive age. Use is generally not established or not recommended for pre-menarchal children or older adults (postmenopausal). During lactation, use is conditional, and caution is recommended as the drug is known to be excreted into human milk.

What should I know about interactions with other medicines?

The interaction profile for Cycloreg (Norethisterone) is defined by pharmacokinetic changes and specific non-negotiable co-administration restrictions documented in regulatory labeling.

Interaction Category Official Regulatory Statement
Contraindicated Combinations The co-administration of Norethisterone is formally restricted with Hepatitis C drug regimens containing Ombitasvir/paritaprevir/ritonavir (with or without Dasabuvir), due to the official risk of ALT enzyme elevations. Certain other substances, such as Acitretin, are also classified as contraindicated combinations.
Exposure Modification (Reduced) Medications that induce the CYP3A4 enzyme system may increase the clearance of Norethisterone, leading to reduced systemic concentrations. This group includes certain Anticonvulsants (e.g., Phenytoin) and Anti-infectives (e.g., Rifampicin). Herbal preparations like St. John's Wort are also documented to induce this metabolic pathway.
Exposure Modification (Increased) Strong or moderate CYP3A4 inhibitors may decrease the clearance of Norethisterone, resulting in increased systemic concentrations. Examples include certain Antifungals and Grapefruit Juice.
Other Constraints Specific timing rules apply to the co-administration of Ulipristal acetate, where Norethisterone’s effectiveness may be reduced if taken within five days of the former. Additionally, Norethisterone is documented to influence results of certain laboratory tests, including those for hepatic function and coagulation parameters. Special interaction-related considerations apply to patients with impaired liver function due to poor metabolism risk.

Mechanism of Action

How Cycloreg Works

Agonism at the Progesterone Receptor (PR)

Cycloreg is a synthetic progestin that acts as a progesterone receptor agonist. The active ingredient, norethisterone, binds to the nuclear progesterone receptor with high affinity, initiating an intracellular signal transduction cascade.

Modulation of the Hypothalamic-Pituitary-Ovarian Axis

This receptor activation influences the hypothalamic-pituitary-ovarian axis, leading to the inhibition of pituitary hormones that regulate ovarian function, primarily by suppressing the secretion of luteinizing hormone (LH).

Direct Endometrial Effect and Cycle Influence

Concurrently, it acts directly on the endometrium, modifying the tissue and causing a reduction in proliferative activity. This dual mechanism of action modulates the hormonal milieu, influencing the phases of the menstrual cycle.

Dosage and Administration Information

How to Use Cycloreg — Official Administration Guidelines

Cycloreg is a prescription-only medication that is administered exclusively by the oral route as a tablet. The administration protocol is determined by the specific condition being addressed, requiring the regimen to be adapted individually under professional oversight.

Administration Scope Detail
Route of Administration Oral (by mouth).
Official Dosage Range Varies from 2.5 mg to 10 mg daily for regulating uterine bleeding to a potential maximum of 20 mg to 25 mg daily for intensive management of endometriosis.
Frequency Pattern Daily for continuous maintenance therapy, or intermittent/cyclic use for short-term hormonal regulation.

The usage pattern of Cycloreg follows two distinct schedules. For conditions requiring hormonal cycling, a short-term, cyclic course is typically administered for 5 to 10 days per cycle to induce a progestin withdrawal bleed. In contrast, long-term conditions, such as endometriosis, may require continuous daily administration for a minimum course duration of six months.

The 5 mg oral tablet features a functional score (break line), a physical characteristic that permits the tablet to be split. This allows for the precise administration of lower or non-standard dosages, such as the 2.5 mg strength, as required by the tailored regimen. The medication is not indicated for use in the pediatric population.

Recent Clinical Evidence

Research evidence / Overview of studies for Cycloreg

The research evidence for Cycloreg (Norethisterone) comes primarily from clinical studies that examine its use in managing specific hormonal and gynecological conditions characterized by fluctuating or episodic manifestations. These studies, which include Randomized Controlled Trials (RCTs) and various observational settings, help describe how the medicine was studied for its main applications. The findings describe patterns observed in the studies, but research does not determine whether an individual will respond similarly.


Research Evidence for Regulating Menstrual Cycles

Trials primarily included adult and premenopausal women and focused on measuring outcomes related to systemic or functional imbalance in conditions where symptoms may vary in intensity. Researchers carefully measured outcomes like the volume of menstrual blood loss and the time to cessation of acute bleeding. Studies also monitored how changes in cycle regularity were recorded in the observed populations.

The studies report findings describe patterns observed in the studies where heavy bleeding measurements were different during the short-term treatment period. In cases where the menstrual cycle was absent (secondary amenorrhea), the research highlights changes measured during the study period that related to the return of a withdrawal bleed. Findings were mixed; studies observed differences based on the specific dose and length of time the medicine was evaluated in. Comparative evidence is limited.


Evidence in the Management of Endometriosis-Associated Pain

Cycloreg was studied for managing pain associated with endometriosis, a condition marked by functional limitations. The research included premenopausal women with confirmed endometriosis and utilized study contexts relevant in trials assessing short-term or episodic symptom patterns. Studies monitored patient-reported outcomes describing perceived discomfort, such as pain intensity scores for painful periods (dysmenorrhea) and chronic pelvic pain.

Findings describe patterns observed in the studies where some participants reported different outcomes related to physical discomfort over the course of intermediate-term administration. Research highlights changes measured during the study period, where studies report how symptoms evolved in the observed populations used in research exploring how symptoms change over time. However, much of this evidence was observed in some studies where Norethisterone was administered as part of a combination hormonal regimen, meaning the findings related to its use as a single agent are not fully established.


What is Still Uncertain in the Cycloreg Research Base

The evidence highlights what is known — and what is still uncertain about Cycloreg. A key area where certainty remains low is the long-term outcomes and the durability of the treatment effects after the medicine is stopped. Furthermore, comparative evidence is lacking against several newer drug formulations that have entered the market since the initial studies were conducted.

Key Studies & References Norethindrone Acetate Tablets USP, 5 mg - DailyMed

Frequently Asked Questions (FAQ)

Common questions about Cycloreg (FAQ)


Q: How is Cycloreg different from other medicines that treat the same condition?

Official regulatory documents classify Cycloreg's active ingredient, norethisterone, as a single-ingredient synthetic progestogen (progestin). This means the formulation is designed to deliver only the hormone-regulating effects of progesterone, without the simultaneous activity of estrogen.


Q: Does Cycloreg treat the root cause of the condition or just the symptoms?

The medicine is described as acting as a progesterone receptor agonist, which means it mimics natural progesterone to modulate the hormonal environment. This mechanism helps to influence the phases of the menstrual cycle and stabilize the uterine lining (endometrium), which is the foundation for managing symptoms related to hormonal imbalance.


Q: How long does it usually take to feel the effects of Cycloreg?

Official documents state that Cycloreg is administered in courses ranging from a few days (for acute bleeding) up to six months (for long-term conditions like endometriosis). While clinical studies monitored changes in bleeding and pain over these different treatment periods, official product information does not provide a fixed timeframe for when an individual patient can expect to feel the effects.


Q: Is it normal to feel a mild headache when first starting Cycloreg?

According to official adverse reaction data, headache is documented as a very common side effect. Furthermore, some reactions, such as menstrual irregularities, are officially documented to occur more frequently during the initial months of treatment.


Q: Can Cycloreg cause changes in mood or sleep patterns?

Official prescribing information lists changes in mood, including depressed mood or depression, as a common side effect. Insomnia, a disturbance in sleep patterns, is also noted as a possible adverse reaction in some regulatory documents.


Q: Is there a different way to take Cycloreg if I have trouble swallowing pills?

Cycloreg is administered exclusively by the oral route as a tablet. The 5 mg tablet features a functional score (break line) that allows it to be split for dose adjustments. However, official information does not provide specific instructions for crushing the tablet or alternatives for patients who have persistent difficulty swallowing.


Q: Is Cycloreg available as a generic version, and is it the same as the brand name?

The active component in Cycloreg is norethisterone, which is available generically. Regulatory bodies generally consider the generic forms of a drug to be therapeutically equivalent to the brand-name product if they meet the same high standards for quality and performance.


Q: What happens if I accidentally miss a dose of Cycloreg?

Official regulatory guidance describes instructions for a missed dose, typically stating that it is taken as soon as it is remembered. If it is close to the time for the next scheduled dose, the label contains specific guidance on when it should be skipped. The product label also states that doses are not to be doubled.


Q: What if I forget what time of day I am supposed to take my Cycloreg?

Official administration guidelines indicate that for optimal maintenance of consistent hormone levels, the dose is generally taken at approximately the same time every day. If the usual timing is forgotten, the product label contains specific guidance regarding when a dose is to be taken or skipped.


Q: What is the evidence regarding Cycloreg's effectiveness in real-world use?

Research evidence for Cycloreg includes data gathered from both controlled clinical trials and observational settings. While observational data helps describe patterns seen in diverse patient populations, regulatory sources caution that research findings cannot determine the outcome for any individual patient.


Q: Why did my doctor choose Cycloreg over another drug option?

Official therapeutic indications state that Cycloreg is indicated for the management of specific hormonal conditions, such as heavy menstrual bleeding, certain types of amenorrhea, and endometriosis. A healthcare provider selects the treatment based on a patient’s specific diagnosed condition and their comprehensive medical profile.


Q: Does Cycloreg have any known effects on fertility or reproductive health?

The drug is known to inhibit pituitary hormones that regulate ovarian function, which is the mechanism for its therapeutic action in cycle regulation. For safety, official information states the product is strictly contraindicated during known or suspected pregnancy due to the risk of fetal harm.


Q: Is it okay to have an alcoholic drink occasionally while taking Cycloreg?

A direct, universal contraindication between Cycloreg and alcohol is not generally listed in regulatory documents. Some official sources caution that excessive consumption may exacerbate common side effects such as headache and nausea.


Q: What does it mean if Cycloreg is 'metabolized by the liver'?

The term 'metabolized by the liver' refers to the process where the active ingredient is chemically broken down and processed, mainly by the CYP3A4 enzyme system, for its distribution and subsequent elimination from the body. This process is the reason why interactions with other liver-affecting medicines are a documented consideration.


Q: How do I know if Cycloreg is actually working for me?

The general therapeutic purpose of Cycloreg is to achieve regulation of the menstrual cycle and manage related symptoms. During clinical trials, effectiveness was assessed by measuring outcomes such as changes in blood loss volume, the return of cycle regularity, and patient-reported pain scores.


Q: Does Cycloreg affect my ability to drive or operate machinery?

Official safety information reports side effects such as dizziness and headache as common reactions. Official labeling notes that because these effects could potentially impair performance, the individual response to the medication is to be considered before engaging in activities like driving or operating machinery.


Q: Can I travel with Cycloreg, and are there special precautions?

Official storage requirements state that the product is to be maintained below 25 C and protected from light and moisture. For stability, regulatory information indicates the product is to remain in its original package during storage and transport.


Q: How does Cycloreg affect blood pressure or heart rate?

Official warnings state the medication is contraindicated in women with uncontrolled hypertension and requires cautious use for those with existing cardiac conditions. This is primarily documented due to the potential for the drug to cause fluid retention, which can influence cardiovascular factors.


Q: Does Cycloreg interact with common vitamins like Vitamin D or B12?

While the product is officially documented to influence the results of certain laboratory tests, a direct, specific drug-to-vitamin interaction is not generally stated for common vitamins like D or B12. Some hormonal agents, however, are associated with regulatory notes about changes in the levels of certain B vitamins.


Q: What is the function of the inactive ingredients in Cycloreg?

Inactive ingredients, which are referred to as excipients in official documents, are substances added to the formulation that do not have a therapeutic effect. Their function is to create the stable oral tablet form, ensure the product's shelf-life, and assist the body with proper drug absorption.


Q: Are there specific times of day Cycloreg is known to be more effective?

Official administration guidelines indicate that to maintain consistent levels of the active ingredient, the medication is generally taken at the same time every day.


Q: Can taking Cycloreg cause temporary or permanent changes to vision?

Official safety information states that rare, serious side effects, such as thromboembolic events, have the potential to affect vision. Regulatory labeling includes a specific warning that the development of certain vision issues may indicate a need for professional evaluation, such as checking for retinal vein thrombosis.

How should Cycloreg be stored and disposed of?

The storage and disposal of Cycloreg (Norethisterone) must align strictly with official regulatory requirements to ensure product stability and safety.

Storage Requirements

Condition Official Requirement
Temperature Store below 25 C (Controlled Room Temperature is typically 20 C to 25 C).
Protection Keep the medicine protected from light and moisture.
Container Store in the original package to maintain the stability conditions.
Safety Keep this and all medications out of the sight and reach of children.
Stability The shelf-life is established for five years, provided the mandatory storage conditions are followed.

Disposal Instructions

Expired or unused tablets should not be discarded via household waste or wastewater. The officially preferred method for disposal is through a community drug take-back disposal program when available. If no local program is accessible, specific governmental instructions must be followed for the safe discarding of hormonal medications.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cycloreg found in:

A-Z Index: